X0202 SCHEDULE 13G 0001857522 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 08/13/2026 0001770069 MapLight Therapeutics, Inc. 56565P103 800 Chesapeake Drive Redwood City CA 94063 Rule 13d-1(c) Nan Fung Group Holdings Limited b D8 0 2915874 0 2915874 2915874 N 5.5 CO NF Investment Holdings Limited b D8 0 2911774 0 2911774 2911774 N 5.5 CO Nan Fung Life Sciences Holdings Limited b D8 0 1283052 0 1283052 1283052 N 2.4 CO NFLS Platform Holdings Limited b E9 0 671606 0 671606 671606 N 1.3 CO Pivotal Life Sciences Holdings Limited b E9 0 611446 0 611446 611446 N 1.2 CO Pivotal Partners Ltd b E9 0 611446 0 611446 611446 N 1.2 CO Pivotal bioVenture Partners Fund II G.P. Ltd b E9 0 611446 0 611446 611446 N 1.2 CO Pivotal bioVenture Partners Fund II, L.P. b E9 0 611446 0 611446 611446 N 1.2 PN NFLS Beta Limited b D8 0 671606 0 671606 671606 N 1.3 CO Permwell Management Limited b E9 0 1628722 0 1628722 1628722 N 3.1 CO MapLight Therapeutics, Inc. 800 Chesapeake Drive, Redwood City, CA 94063 The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of common stock, par value $0.0001 per share (the "Common Stock") of MapLight Therapeutics, Inc. (the "Issuer") are: (i) Nan Fung Group Holdings Limited ("NFGHL") (ii) NF Investment Holdings Limited ("NFIHL") (iii) Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences") (iv) NFLS Platform Holdings Limited ("NFLS Platform") (v) Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences") (vi) Pivotal Partners Ltd ("Pivotal Partners") (vii) Pivotal bioVenture Partners Fund II G.P. Ltd ("Pivotal II GP") (viii) Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II," and together with Pivotal Life Sciences, Pivotal Partners, and Pivotal II GP, the "Pivotal Entities") (ix) NFLS Beta Limited ("NFLS Beta") (x) Permwell Management Limited ("Permwell") The address of the principal business office of each of the Pivotal Entities is 501 Second Street, Suite 200, San Francisco, CA 94107. The principal business address of each of NFGHL and Permwell is 17th Floor, AIRSIDE, 2 Concorde Road, Kai Tak, Hong Kong. The registered office address of each of NFIHL, Nan Fung Life Sciences and NFLS Beta is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands. The registered office address of NFLS Platform is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands. Pivotal II is a Cayman Islands exempted limited partnership. Pivotal II GP is a Cayman Islands exempted company. Pivotal Partners is a Cayman Islands exempted company. Pivotal Life Sciences is a Cayman Islands exempted company. Nan Fung Life Sciences, NFIHL, NFGHL, and NFLS Beta are incorporated in the British Virgin Islands. NFLS Platform and Permwell are incorporated in the Cayman Islands. Y The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. Pivotal II directly holds 611,446 shares of Common Stock. NFLS Beta directly holds 671,606 shares of Common Stock. Permwell directly holds 1,628,722 shares of Common Stock. Pivotal II GP is the general partner of Pivotal II, and is wholly owned by Pivotal Partners. Pivotal Partners is wholly owned by Pivotal Life Sciences. Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences, and Nan Fung Life Sciences is wholly owned by NFIHL, which is wholly owned by NFGHL. NFLS Beta is wholly owned by NFLS Platform, which is wholly owned by Nan Fung Life Sciences. Permwell is wholly owned by NFIHL. The members of the Executive Committee of NFGHL (the "Excomm") make investment decisions with respect to the securities of the Issuer held by NFLS Beta and Permwell. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Heqing Huang and Mr. Chun Wai Nelson Tang are the members of the Excomm. The members of the Excomm and the members of the Life Sciences Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal II. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Life Sciences Committee of NFGHL. The amounts set forth in Rows 5 through 9 of the cover page of NFGHL also reflect 3,500 shares of Common Stock held by Mr. Bisgaard and 600 shares of Common Stock held by Mr. Hopfner. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock held by Messrs. Bisgaard and Hopfner. The information required by this item with respect to each Reporting Person is set forth in Row 11 of the cover pages to this Schedule 13G. The ownership percentages are based on 52,848,208 shares of voting Common Stock outstanding, consisting of (i) 43,650,321 shares of voting Common Stock outstanding as of August 7, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on August 13, 2026 and (ii) 9,197,887 shares of voting Common Stock issued by the Issuer in a private placement, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on August 13, 2026. The information required by this item with respect to each Reporting Person is set forth in Row 5 of the cover pages to this Schedule 13G. The information required by this item with respect to each Reporting Person is set forth in Row 6 of the cover pages to this Schedule 13G. The information required by this item with respect to each Reporting Person is set forth in Row 7 of the cover pages to this Schedule 13G. The information required by this item with respect to each Reporting Person is set forth in Row 8 of the cover pages to this Schedule 13G. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 1 - Joint Filing Agreement Nan Fung Group Holdings Limited /s/ Tang Chun Wai Nelson 08/20/2026 NF Investment Holdings Limited /s/ Tang Chun Wai Nelson 08/20/2026 Nan Fung Life Sciences Holdings Limited /s/ Sun Xintong 08/20/2026 NFLS Platform Holdings Limited /s/ Sun Xintong 08/20/2026 Pivotal Life Sciences Holdings Limited /s/ Sun Xintong 08/20/2026 Pivotal Partners Ltd /s/ Sun Xintong 08/20/2026 Pivotal bioVenture Partners Fund II G.P. Ltd /s/ Peter Tuxen Bisgaard 08/20/2026 Pivotal bioVenture Partners Fund II, L.P. Pivotal bioVenture Partners Fund II G.P. Ltd 08/20/2026 /s/ Peter Tuxen Bisgaard 08/20/2026 NFLS Beta Limited /s/ Sun Xintong 08/20/2026 Permwell Management Limited /s/ Tang Chun Wai Nelson 08/20/2026